2 Materials and methods 2.1 Search strategy A systematic literature search was performed using the PubMed, Web of Science, Embase, and Cochrane databases, as well as the China National Knowledge Infrastructure (CNKI) in December 2023 using the following search terms: (Hashimoto Disease[MeSH Terms]) OR (Disease, Hashimoto[Other Term]) OR (Chronic Lymphocytic Thyroiditis[Other Term]) OR (Chronic Lymphocytic Thyroiditides[Other Term]) OR (Lymphocytic Thyroiditides, Chronic[Other Term]) OR (Lymphocytic Thyroiditis, Chronic[Other Term]) OR (Thyroiditides, Chronic Lymphocytic[Other Term]) OR (Thyroiditis, Chronic Lymphocytic[Other Term]) OR (Hashimoto Struma[Other Term]) OR (Hashimotos Struma[Other Term]) OR (Hashimotos Syndrome[Other Term]) OR (Hashimoto Syndrome[Other Term]) OR (Hashimotos Syndromes[Other Term]) OR (Hashimotos Syndrome[Other Term]) OR (Syndrome, Hashimotos[Other Term]) OR (Syndromes, Hashimotos[Other Term]) OR (Hashimotos Disease[Other Term]) OR (Disease, Hashimotos[Other Term]) OR (Hashimotos Disease[Other Term]) OR (Hashimoto Thyroiditis[Other Term]) OR (Hashimoto Thyroiditides[Other Term]) OR (Thyroiditides, Hashimoto[Other Term]) OR (Thyroiditis, Hashimoto[Other Term]) AND (selenium[MeSH Terms]) OR (Vitamin d[MeSH Terms]) OR (Myo-inositol[MeSH Terms])

In the TRIUMPH-1 Phase 3 trial, participants on the maximum dose of retatrutide (12 mg) lost an average of 28.3% of their body weight after 80 weeks, and up to 30.3% after 104 weeks in the study extension
For further information, we recommend consulting scientific literature or specialised websites before placing an order
Products referred to as "GLP-1 patches" do not contain GLP-1 receptor agonists
Serious Medical Conditions Anyone with liver disease, kidney dysfunction, or active metabolic disorders should consult their physician before starting glutathione therapy
NAD Plus and NAD+ are the same molecule, so bioavailability cannot differ